QIAGEN CEO: Company’s 'very open to engage' on review

QIAGEN CEO: Company’s 'very open to engage' on review

QIAGEN CEO: Company’s 'Very Open to Engage' on Strategic Review Amid Shareholder Value Discussions

QIAGEN (QGEN) has indicated openness to strategic discussions that could enhance shareholder value, according to outgoing CEO Thierry Bernard, who addressed investor inquiries during the company’s February 5 earnings call. While declining to confirm rumors of potential takeover activity, Bernard acknowledged the ongoing consolidation in the diagnostics sector and emphasized the company’s focus on executing its long-term growth plan according to CEO Thierry Bernard.

The biotech firm has faced heightened speculation about its strategic direction since Bernard announced his planned departure in November 2025. During the call, he reiterated that the board is prioritizing a thorough search for a successor, describing the process as "advancing very well" but requiring "the necessary time" to identify the "best person for the job" as Bernard stated. Meanwhile, management remains committed to operational stability, with Bernard highlighting Qiagen's recent financial performance as evidence of its resilience.

For 2025, the company reported net sales of $2.09 billion, reflecting 5% growth at constant exchange rates, aligning with its guidance of 4-5% growth. Fourth-quarter sales rose 1% year-over-year to $540 million according to financial reports. Looking ahead, Qiagen projected at least 5% sales growth for 2026, underscoring its confidence in sustaining momentum.

The CEO's remarks come as Qiagen navigates a dynamic market landscape. In January 2026, Bloomberg reported that the company was "weighing strategic options, including a potential sale," citing unnamed sources as reported by Bloomberg. While Bernard reiterated Qiagen's policy of not commenting on "rumors," he left the door open for engagement, stating the company is "open for discussion" on initiatives that could unlock value.

With leadership transition plans underway and a strategic review in play, investors will likely monitor Qiagen's next steps closely as it balances growth execution with potential corporate transformation.

According to FierceBiotech, Seeking Alpha, and QIAGEN internal statements: FierceBiotech, Seeking Alpha, and QIAGEN internal statements.